FDA approves third Vertex CF drug

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said FDA approved Symdeko tezacaftor/ivacaftor to treat cystic fibrosis in patients ages 12 and older who have 2 copies of

Read the full 242 word article

User Sign In